

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

**VOLUNTARY ANNOUNCEMENT
CANCELLATION OF H SHARES REPURCHASED
FROM 25 SEPTEMBER 2019 TO 13 JANUARY 2020**

On 6 June 2019, YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) held the annual general meeting, the 2019 second H shareholders class meeting and 2019 second domestic shareholders class meeting, at which the shareholders of the Company granted a general mandate to the board of directors (the “**Board**”) of the Company to repurchase the Company’s H shares (the “**H Shares**”) on The Stock Exchange of Hong Kong Limited with an aggregate nominal value of not exceeding 10% of the aggregate nominal value of H Shares in issue as at the date of passing of the related special resolution.

The Company has repurchased the H Shares on 7 occasions from 25 September 2019 to 13 January 2020. Details of the repurchases conducted were set out in the Next Day Disclosure Returns published on 25 September 2019, 26 September 2019, 27 September 2019, 30 September 2019, 14 November 2019, 18 November 2019 and 13 January 2020, respectively. The Company has repurchased a total of 4,427,400 H Shares, representing 2.029% of the total number of H Shares and 0.996% of the total number of issued shares (“**Shares**”) of the Company as at 9 April 2020. The total amount paid for the above repurchases conducted from 25 September 2019 to 13 January 2020 was HK\$176,244,114.52 (excluding the commission and other expenses).

The Company has cancelled the above repurchased 4,427,400 H shares. For more details, please refer to the Next Day Disclosure Return published on 9 April 2020.

As at the date of this announcement, the total number of Shares is 444,392,650 (which comprises 218,192,650 H Shares and 226,200,000 domestic shares).

This announcement is made by the Company on a voluntary basis.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC

9 April 2020

As of the date of this announcement, the board of directors of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfu and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. FU Hailiang and Mr. ZHAO Dayao as independent non-executive directors.